Recombinant Human IL-29/IFN-lambda 1 Protein, CF 1598-IL-025/CF from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human IL-29/IFN-lambda 1 Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $408.00Supplier Page View Company Product Page
Catalog Number1598-IL-025/CF
Size25 ug
ApplicationsBioactivity
FormatLyophilized from a 0.2 µm filtered solution in PBS
Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 26-35 kDa, reducing conditions
Theoretical: 21.4 kDa
Conjugate/TagUnconjugated
SpeciesHuman
Molecule NameIL-29/IFN-lambda 1
Source/Expression SystemNS0-derived Recombinant Human IL-29/IFN-lambda 1 Protein, CF
NCBI Full Gene Nameinterferon lambda 1
NCBI Gene AliasesIL29, IL-29
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Dose-dependent IL-29 activation of TLR4 signalling drives eosinophil infiltration in chronic rhinosinusitis with nasal polypsActa Otorhinolaryngol ItalApril 30, 2026Yu Zhong, Huijuan Yan, Yuren Zhou, Nanlan Huang, Jingkun Liand IL-29 stimulation groups with different concentrations (10, 25, 50, and 100 ng/mL, R&D Systems, 1598-IL-025/CF). IL-29 was added to the culture medium, and after 24 hours of stimulation, cells and supernatants were

(2) Dose-dependent IL-29 activation of TLR4 signalling drives eosinophil infiltration in chronic rhinosinusitis with nasal polypsActa Otorhinolaryngol ItalApril 30, 2026Yu Zhong, Huijuan Yan, Yuren Zhou, Nanlan Huang, Jingkun Liand IL-29 stimulation groups with different concentrations (10, 25, 50, and 100 ng/mL, R&D Systems, 1598-IL-025/CF). IL-29 was added to the culture medium, and after 24 hours of stimulation, cells and supernatants were

(3) CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2Mol MedMarch 28, 2026Xiaohe Liu, Marvin A. Ssemadaali, Harikrishnan Radhakrishnan, Juan Arredondo, Harold S. Javitz, Satya Dandekar, Parijat BhatnagarRecombinant human interferon (rhIFN) proteins from R&D systems (IFN-β [Cat# 8499-IF-010/CF], IFN-λ1 [Cat# 1598-IL-025/CF], IFN-λ2 [Cat# 8417-IL-025/CF]) and IFN-α2 from InvivoGen [Cat# rcyc-hifna2b] were used as controls.

(4) Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cellsPLOS BiologyJanuary 26, 2026Krupakar V. Subramaniam, Hui Jing Lim, Bao Wang, Valia T. Mihaylova, Evrett N. Thompson, Diane S. Krause, Ellen F. Foxman1% P/S. Recombinant interferons and inhibitors Recombinant IFNs included IFNλ1 (R&D Systems, Cat# 1598-IL-025/CF), IFNλ2 (R&D Systems, Cat# 1587-IL-025), and IFNβ (PBL Assay Science Cat# 11415). For all HBEC and HFF

(5) Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1Life science allianceJune 1, 2023Nchioua R, Schundner A, Klute S, Koepke L, Hirschenberger M, Noettger S, Fois G, Zech F, Graf A, Krebs S, et al.[Cat#8499-IF-010/CF; R&D Systems], and γ [Cat#285-IF-100/CF; R&D Systems] using 5, 50, and 500 IU/ml or IFN-λ1 [Cat#1598-IL-025/CF; R&D Systems] using 1, 10, and 100 ng/ml) in 0.5 ml of medium. 6–12 h after the first stimulation, the

(6) The E3 ligase subunit FBXO45 binds the interferon-λ receptor and promotes its degradation during influenza virus infectionThe Journal of biological chemistryDecember 1, 2022Tsai M, Osman W, Adair J, ElMergawy R, Chafin L, Johns F, Farkas D, Elhance A, Londino J, Mallampalli RK.

(7) Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune ResponsesCancer immunology researchApril 1, 2022Fedoriw A, Shi L, O'Brien S, Smitheman KN, Wang Y, Hou J, Sherk C, Rajapurkar S, Laraio J, Williams LJ, et al.

(8) Astrocyte Control of Zika Infection Is Independent of Interferon Type I and Type III ExpressionBiologyJanuary 15, 2022Das M, Smith ML, Furihata T, Sarker S, O'Shea R, Helbig KJ.

(9) The protective effects of Olmesartan against interleukin-29 (IL-29)-induced type 2 collagen degradation in human chondrocytesBioengineeredJanuary 11, 2022Yunlong Liu, Junyi Liu, Yan Ma, Yongyong Zhang, Qiong Chen, Xin Yang, Yanchun Shangcompound Olmesartan (144689-24-7) was purchased from Sigma-Aldrich, USA. The recombinant human IL-29 (1598-IL-025/CF) was from R&D Systems, USA. For the cell treatment experiment, T/C-28a2 cells were plated in 60-mm or

(10) Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2Nature communicationsDecember 7, 2021Hatton CF, Botting RA, Dueñas ME, Haq IJ, Verdon B, Thompson BJ, Spegarova JS, Gothe F, Stephenson E, Gardner AI, et al.

(11) Intracellular lipid droplet accumulation occurs early following viral infection and is required for an efficient interferon responseNature communicationsJuly 14, 2021Monson EA, Crosse KM, Duan M, Chen W, O'Shea RD, Wakim LM, Carr JM, Whelan DR, Helbig KJ.

(12) Interferon Lambda Delays the Emergence of Influenza Virus Resistance to OseltamivirMicroorganismsJune 1, 2021Medaglia C, Zwygart AC, Silva PJ, Constant S, Huang S, Stellacci F, Tapparel C.

(13) Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activationArthritis research & therapyMay 21, 2021Hawerkamp HC, Domdey A, Radau L, Sewerin P, Oláh P, Homey B, Meller S.

(14) Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilitiesCell reportsMay 18, 2021Hayn M, Hirschenberger M, Koepke L, Nchioua R, Straub JH, Klute S, Hunszinger V, Zech F, Prelli Bozzo C, Aftab W, et al.

(15) Human Intestinal Organoids Recapitulate Enteric Infections of Enterovirus and CoronavirusStem cell reportsMarch 9, 2021Zhao X, Li C, Liu X, Chiu MC, Wang D, Wei Y, Chu H, Cai JP, Hau-Yee Chan I, Kak-Yuen Wong K, et al.

(16) Interferon-λ Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 PathwayCell reportsOctober 6, 2020Syedbasha M, Bonfiglio F, Linnik J, Stuehler C, Wüthrich D, Egli A.

(17) Interferon-Dependent and Respiratory Virus-Specific Interference in Dual Infections of Airway EpitheliaScientific reportsJune 24, 2020Essaidi-Laziosi M, Geiser J, Huang S, Constant S, Kaiser L, Tapparel C.

(18) Dendritic cells-derived interferon-λ1 ameliorated inflammatory bone destruction through inhibiting osteoclastogenesisCell death & diseaseJune 2, 2020Chen Y, Wang Y, Tang R, Yang J, Dou C, Dong Y, Sun D, Zhang C, Zhang L, Tang Y, et al.infectious diseases. Materials and methods Cells, media, and reagents Recombinant Human IFN-λ1 Protein (1598-IL-025/CF), recombinant murine TRANCE/RANKL (462-TEC-010/CF) and recombinant murine M-CSF (416-ML-010) were from

(19) RIG-I-like receptor activation drives type I IFN and antiviral signaling to limit Hantaan orthohantavirus replicationPLoS pathogensApril 1, 2020Kell AM, Hemann EA, Turnbull JB, Gale M Jr.of relevant stimuli. Recombinant human IFNλ/IL29, IFNα2, and IFNγ were purchased from R&D Systems (1598IL025CF, 285-IF-100, 11105–1). Recombinant human IFNβ was provided by Toray Industries. Focus-forming unit

(20) Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potencyCytokineJanuary 1, 2020Chung JH, Hong SH, Seo N, Kim TS, An HJ, Lee P, Shin EC, Kim HM.

Be the First to Write a Review!

Acta Otorhinolaryngol Ital

Acta Otorhinolaryngol Ital

Recombinant Human IL-29/IFN-lambda 1 Protein, CF from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (48)

Reviews

Recombinant Human IL-29/IFN-lambda 1 Protein, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map